Antibiotic De-escalation Experience in the Setting of Emergency Department: A Retrospective, Observational Study

Silvia Corcione 1,2, Simone Mornese Pinna 1, Tommaso Lupia 3,*, Alice Trentalange 1, Erika Germanò 1, Rossana Cavallo 4, Enrico Lupia 1 and Francesco Giuseppe De Rosa 1,2

1 Department of Medical Sciences, University of Turin, 10126 Turin, Italy; silvia.corcione@unito.it (S.C.); simone.mornese.pinna@unito.it (S.M.P.); alice.trentalange@unito.it (A.T.); enrico.lupia@unito.it (E.L.); francescogiuseppe.derosa@unito.it (F.G.D.R.)
2 Tufts University School of Medicine, Boston, MA 02129, USA
3 Infectious Diseases Unit, Cardinal Massaia Hospital, 14100 Asti, Italy
4 Microbiology and Virology Unit, University of Turin, 10126 Turin, Italy; rossana.cavallo@unito.it
* Correspondence: tommaso.lupia89@gmail.com; Tel.: +39-0141-486-404 or +39-3462-248-637

Abstract: Background: Antimicrobial de-escalation (ADE) is a part of antimicrobial stewardship strategies aiming to minimize unnecessary or inappropriate antibiotic exposure to decrease the rate of antimicrobial resistance. Information regarding the effectiveness and safety of ADE in the setting of emergency medicine wards (EMW) is lacking. Methods: Adult patients admitted to EMW and receiving empiric antimicrobial treatment were retrospectively studied. The primary outcome was the rate and timing of ADE. Secondary outcomes included factors associated with early ADE, clinical, biochemical, and microbiological perspective, particularly in the critical care setting [4]. However, there is no universal agreement on the definition and time frame of ADE than critically ill patients [2]. This practice generated a selection effect that ultimately delayed the incorporation of ADE into evidence-based guidelines throughout hospitals.

1. Introduction

Antimicrobial stewardship (AS) is increasingly recognized as an important multifaceted tool for minimizing unnecessary or inappropriate antibiotic exposure and thereby reducing the rate of antimicrobial resistance (AMR) and associated healthcare costs [1]. AS initiatives strongly promote early de-escalation treatment strategies and thus narrow the spectrum or reduce the number of molecules of an empiric antimicrobial treatment once culture results are available.

Antimicrobial de-escalation (ADE) is a critical aspect of AS programmes. It is strictly dependent on multiple factors, such as the early collection of adequate microbiological samples, pathogen identification, and the administration of an initial anti-infective regimen [2,3]. Several authors have attempted to define ADE from a comprehensive temporal, clinical, biochemical, and microbiological perspective, particularly in the critical care setting [4]. However, there is no universal agreement on the definition and time frame of intervention. Furthermore, in the past, moderately ill patients were more likely to receive ADE than critically ill patients [2]. This practice generated a selection effect that ultimately delayed the incorporation of ADE into evidence-based guidelines throughout hospitals.
Thus, ADE, a key recommendation of the Infectious Disease Society of America’s (IDSA) 2007 stewardship program [5], almost disappeared from the 2016 update [6]. The term de-escalation appears just three times in the entire document but nowhere in a prominent position and is mentioned as a possible metric for evaluating AS programmes. Possible reasons for this lack of emphasis are that ADE is not considered a scientific concept, there is no universally accepted definition of ADE, and that the impact of ADE on different metrics and outcomes, such as mortality, length of hospital stay, and infection recurrence, is unknown. However, in several medical settings, there are usually accepted collectivist norms in the decision-making process about treating infections. These discussions frequently receive input from pharmacists and infectious disease and microbiology specialists and emphasise ADE [7].

Nevertheless, several observational studies that focused on ADE in patients admitted to emergency rooms (ERs) and emergency medical wards (EMWs) have reported improved or comparable outcomes with reduced antimicrobial exposure [2]. Similar results have been reported in intensive care unit (ICU) patients [8].

In the ER, the introduction of a sepsis team with the early involvement of infectious diseases consultation (IDC) has been successful in reducing the 14-day mortality. This change also improved the quality of the microbiological work-up, the administration of appropriate antimicrobials, and compliance with the stewardship bundle by reducing the ICU admission rate [9].

Considering the few experiences reported in this setting, the purpose of this study was to examine and describe the prevalence of ADE and the associated factors in a retrospective cohort of patients admitted to a single emergency ward.

2. Materials and Methods

A retrospective, observational study of the role of ADE at different times in a single-centre EMW was conducted. This study was part of a more comprehensive AS program. The study was conducted between January 2016 and November 2017 at the City of Health and Science in Turin, Italy. The primary outcome was the rate of clinical and microbiological ADE on days 2, 3, and 5 after admission. Secondary outcomes included factors associated with early ADE, length of stay, and in-hospital mortality.

Patients were eligible for evaluation if they met all the following criteria: were primarily admitted to the EMW or moved from another ward because of worsening of general conditions; had signs or symptoms suggestive of sepsis or required advanced ventilatory support without an endotracheal tube; had blood cultures (BCs) collected; and were treated with an empirical antibiotic treatment. Demographic data and clinical features were retrieved from the patients’ medical records. For each patient, the quick sequential organ failure assessment (qSOFA) score was calculated on days 1, 3, and 5. Different microbiological samples from other sources were also evaluated in an attempt to establish the source of each patient’s infection.

If multiple episodes of infection were documented for the same patient during the study period, only the first episode was included. When multiple positive BCs were drawn on different days, only the first positive sample was considered. A single positive BC result out of a multiple set for coagulase-negative staphylococci was considered a contamination, and the sample was excluded from the analysis. The antibiotic treatment was classified as either empiric (ET) or targeted (TT). The rate of appropriate empiric antibiotic treatment (AET), inflammatory biomarkers (procalcitonin, PCT; C-reactive protein, C-RP), and ADE were evaluated according to the BC results and number of days since the BCs were obtained (2, 3, and 5 days after collection). Infections occurring up to 48 h after hospital admission were defined as community-acquired infection (CAI), and those occurring >48 h after admission were considered hospital-acquired infection (HAI).

ADE was defined as either reduction in the number of antibiotics, reduction of the antimicrobial spectrum, or targeted de-escalation according to the microbiological results. The reasons for ADE were categorized as clinical, independent from the microbiology
results and including disappearance or improvement of signs and symptoms of systemic inflammatory-response syndrome; microbiological (also called targeted de-escalation); laboratory biomarker- or IDC-driven. An antimicrobial treatment was defined as microbiologically appropriate if the isolate was susceptible in vitro to $\geq 1$ ET. ADE was retrospectively evaluated and was carried out within EMW by physicians who worked in EMW during the period of the study.

2.1. Statistical Analysis

Data were collected in an Excel spreadsheet and analysed using StatView 4.0 (StatView 4.0, JMP software, SAS institute, Cary, NC 27513). Continuous variables are reported as mean (standard deviation) or median (interquartile range). Categorical variables are reported as absolute number (percentage). Nonparametric tests (Wilcoxon, Mann-Whitney, chi-squared, and Fisher’s exact tests) were used for univariate analyses. For categorical variables, chi-squared and Fisher’s tests were used depending on the contingency tables distribution. Non-parametric tests (Wilcoxon and Mann-Whitney) were used for continuous variables and chi-squared and Fisher’s tests for categorical variables. Factors presenting a significant level ($p < 0.05$) at univariate analyses were included in multivariate analyses to assess for risk factors associated with death as an outcome.

2.2. Ethics

The study was approved by the Hospital Medical Direction (Protocol No. 0115709). Data were collected in compliance with Italian laws on privacy protection.

3. Results

The study population consisted of 336 patients admitted to EMW, of which 58% (194) were male. The median age of all patients was 70 years (IQR: 60–80). During the preceding six months, 73.8% (248) of patients had at least one previous hospitalization, and half of those (51%) received antibiotics at that time. An active underlying malignancy was recorded in 44% of patients. The mean length of hospital stay was 17 days (IQR: 10–27.5) (Table 1).

Of the 336 BCs collected, 29% (96) were positive, with 8% being polymicrobial. The source of infection was the respiratory tract in 38% of cases, the urinary tract in 22%, intra-abdominal in 21%, and the skin and skin structure in 9%. The majority of infections (73%) were identified as CAI, and 27% were HAI.

Gram-positive organisms were more frequently isolated from BCs than gram-negative organisms (63% vs 34%); S. epidermidis (28%) and S. aureus (25%) were prevalent. Overall, the rate of methicillin-resistance was 13%. Among the gram-negative isolates, E. coli (42%) was the most common, followed by K. pneumoniae (11%). The rate of extended-spectrum beta-lactamases (ESBL)-producing Enterobacteriaceae was 8%, while carbapenemases-producing K. pneumoniae (KPC) was isolated from 6% of BCs; Candida species were isolated from 3% of BCs, mostly C. albicans. An ET was administered to 97% of patients. Fluconazole and caspofungin were the first choices for suspected candidemia (7%).

The ADE Strategy

The most frequently prescribed empirical agents were ureidopenicillins (25.1%, $n = 40$), carbapenems (13.6%, $n = 33$), glycopeptides (13.7%, $n = 44$), fluoroquinolones (9.6%, $n = 31$), and third-generation cephalosporins (6.7%, $n = 16$). An initial regimen that combined two agents was prescribed in 54.8% ($n = 184$) of cases. The overall rate of prescription appropriateness was 58.3%, of inappropriateness was 40.0%, and of uncertain appropriateness was 2.7%. Overall, ADE was performed in 33% (111) of the patients.
Table 1. Characteristics of patients according to de-escalation rate at day 5.

|                          | Overall     | De-escalation | No De-escalation | p Value |
|--------------------------|-------------|---------------|------------------|---------|
|                          | n = 336     | n = 111       | n = 225          |         |
| Age (years)              | 68 ± 15     | 64 ± 14       | 68 ± 15          | 0.52    |
| Male                     | 194 (58%)   | 57 (29%)      | 137 (71%)        | 0.75    |
| Diabetes mellitus        | 95 (28%)    | 27 (28%)      | 68 (72%)         | 0.68    |
| Solid malignancies       | 94 (28%)    | 30 (32%)      | 64 (68%)         | 0.64    |
| Hematologic Malignancies | 55 (16%)    | 16 (29%)      | 39 (71%)         | 0.86    |
| Chronic renal failure    | 101 (30%)   | 27 (27%)      | 74 (73%)         | 0.38    |
| Transplant               | 15 (4%)     | 6 (40%)       | 9 (60%)          | 0.39    |
| COPD                     | 71 (21%)    | 18 (25%)      | 53 (75%)         | 0.33    |
| Cardiopathies            | 188 (56%)   | 58 (31%)      | 130 (69%)        | 0.72    |
| Cirrhosis                | 21 (6%)     | 10 (48)       | 11 (52%)         | 0.07    |
| Dialysis                 | 9 (3%)      | 2 (22%)       | 7 (78%)          | 0.6     |
| Total parenteral nutrition | 5 (1%)     | 3 (60%)       | 2 (40%)          | 0.14    |
| Previous antibiotic therapies (<6 months) | 171 (51%) | 49 (29%) | 122 (71%) | 0.56 |
| Previous steroids therapy (<3 months) | 77 (23%) | 21 (27) | 56 (73) | 0.54 |
| Admission from hospitalisation (<6 months) | 250 (74%) | 74 (30%) | 176 (70%) | 0.74 |
| Admission from health-care facilities or other wards | 248 (74%) | 77 (31%) | 171 (76%) | 0.73 |
| Central venous catheters at time of admission | 125 (37%) | 40 (32%) | 85 (68%) | 0.55 |
| B-D-glucan (ng/mL)      | 83.94       | 48.09         | 100.38           | 0.17    |
| Creatinine day 1 (mg/dL) | 1.81        | 1.47          | 1.95             | 0.28    |
| Creatinine day 3 (mg/dL) | 1.71        | 1.42          | 1.83             | 0.46    |
| Creatinine day 5 (mg/dL) | 1.61        | 1.3           | 1.76             | 0.98    |
| qSOFA ≥ 1 day 1         | 85 (25%)    | 26 (31%)      | 59 (69%)         | 0.7     |
| qSOFA ≥ 1 day 3         | 52 (15%)    | 16 (31%)      | 36 (69%)         | 0.91    |
| qSOFA ≥ 1 day 5         | 34 (10%)    | 11 (32%)      | 23 (68%)         | 0.98    |
| C-RP day 1 (mg/dL)      | 131.95      | 131.47        | 132.15           | 0.01    |
| C-RP day 3 (mg/dL)      | 104.04      | 104.04        | 138.29           | 0.01    |
| C-RP day 5 (mg/dL)      | 78.02       | 68.76         | 81.76            | 0.22    |

Abbreviations: COPD, chronic obstructive pulmonary disease; qSOFA, quick sequential organ failure assessment; C-RP, C-reactive protein.

The ADE rates on days 2 and 3 after the start of ET were 21% and 23%, respectively. Most patients reported a successful ADE at day 5 (56%; n = 67). ADE was generally performed according to clinical, microbiological, or biomarker- or IDC-driven strategies, and rates of 76%, 74%, 50%, and 31%, respectively, were reported, although more than one factor influenced the decision.

Overall discontinuation of antimicrobial therapy until day 5 was 31.5% (n = 35) and was performed in 8, 4, and 23 patients, respectively, on day 2, 3, and 5. Moreover, narrowing of antimicrobial spectrum was performed in 53.1% (n = 59) of patients collected in this study and was carried out in 7, 16, and 36 patients, respectively, on day 2, 3, and 5.

Overall, C-RP was the most commonly used marker of inflammation (80% of cases, of which 87% were on day 1, 84% on day 3, and 75% on day 5), while PCT and beta-D-glucan were available in 50% (67% on day 1, 57% on day 3, and 45% on day 5) and 11% (all performed on day 5) of patients, respectively. Median C-RP values on day 3 were significantly lower in the ADE group than in patients who continued with their original antibiotics (104 mg/L vs 138.3 mg/L, p = 0.01). PCT was detected in 69%, 54%, and 41% of ADE patients on days 1, 3, and 5, respectively; this was not significantly different from patients who did not de-escalate (67%, 59%, and 47% on days 1, 3, and 5, respectively) (Table 1). Conversely, patients who had lower C-RP levels on day 3 de-escalated more significantly than those with higher values (104 mg/L vs. 138 mg/L; p = 0.01). PCT results were excluded from the analysis due to the low number of tests performed. The qSOFA scores on days 2, 3, and 5 were higher in patients who did not de-escalate, although the difference was not significant.
The overall in-hospital mortality rate was 21%, and it was significantly lower among the ADE group than the continuation group (16% vs. 25% \( p = 0.003 \)). The univariate analyses of factors associated with ADE are reported in Table 2.

| TABLE 2. Univariate analysis of mortality according to appropriate treatment and de-escalation rates. |
|-------------------------------------------------|-----------------|-----------------|-----------------|-----------------|
| Overall N = 336 | No Survivors N (%) | Survivors N (%) | \( p \) Value |
|-----------------|-----------------|-----------------|-----------------|
| Empiric Therapy | 325 (97) | 67 (95) | 258 (97) | 0.485 |
| Appropriate empiric therapy | 196 (58) | 31 (44) | 165 (62) | 0.007 |
| Appropriate target therapy | 117 (35) | 16 (23) | 101 (37) | 0.006 |
| De-escalation (or any de-escalation) | 101 (30) | 11 (15) | 90 (34) | 0.013 |

Either an appropriate ET or TT had a protective effect on mortality (62% vs 44%, \( p = 0.007 \) and 37% vs 23%, \( p = 0.006 \)) as well as ADE at any time (34% vs. 15%, \( p = 0.013 \)). Multivariate analysis results (Table 3) indicated that appropriate ET and TT and an ADE strategy applied at any time reduced mortality.

| TABLE 3. Multivariate analysis of factors significantly affecting mortality. |
|-----------------|-----------------|-----------------|
| VARIABLE OR IC 95% |
|-----------------|-----------------|-----------------|
| De-escalation | 0.51 | 0.39–0.65 |
| Appropriate targeted therapy | 0.079 | 0.039–0.16 |
| Appropriate empiric therapy | 0.57 | 1.22–3.59 |

Univariate analysis results showed that there were no characteristics associated with ADE strategies. Of note, the qSOFA score was higher in patients who did not de-escalate, but the difference did not reach statistical significance.

**4. Discussion**

In our study, the overall ADE rate was 33%. The most prescribed empiric antibiotics were ureidopenicillins (25.1%) and carbapenems (13.6%). ADE was performed on day 5 after the start of ET in 56% of patients, on day 3 in 23% of patients, and on day 2 in 21% of patients. ADE was performed by decreasing the number of antibiotics and the spectrum. The overall mortality rate was 21%, and the median in-hospital length of stay was 17 days. Survival was higher among patients who de-escalated (16% vs. 25%, \( p = 0.003 \)). Multivariate analysis results showed that ADE strategies (\( p = 0.013 \)) and appropriate antibiotic treatment, either empiric (\( p = 0.007 \)) or targeted (\( p = 0.006 \)), were associated with reduced mortality. Our results are in line with other studies on severely ill patients [10–12]. The overall rate of methicillin resistance (13%) and multi-drug resistant Enterobacteriaceae (14%) hampered the possibility of ADE and could partially explain the low rate of ADE reported here.

Interestingly, ADE was performed on day 5 in 56% of patients and within the first three days in 44% of patients, which is when preliminary microbiological data are usually available.

In a clinical setting, the decision to de-escalate a treatment is a multi-layered decision that relies not only on microbiological data but also on clinical stability, source control, and IDC and is definitively a result of a composite evaluation in the EMW. Interestingly, the severity of the illness at the time of admission to the EMW did not influence our decision to change treatment, as the qSOFA scores were not significantly different between the groups. However, patients with negative qSOFA scores tended to de-escalate more frequently than the others.

C-RP and PCT levels are frequently used as surrogates for clinical response in patients with suspected or proven infection [13]. In our analysis, the C-RP value at day 3 was statistically associated with ADE. Taking note of C-RP levels could reduce the length of
treatment with antibiotics, but as an indicator, the C-RP level has poor specificity and low diagnostic accuracy. It cannot reliably distinguish infectious from non-infectious processes, and it is not a predictor of mortality [14,15]. Since the significance of PCT levels has not been systematically assessed among patients, we did not include them in the analysis. To suggest the timing of ADE to physicians, serial determination of PCT levels will be more useful than a single determination. However, PCT values during the first five days were not associated with survival in 48 patients with sepsis, suggesting that C-RP and PCT are not reliable markers of prognosis and should not be independently considered for predicting outcomes.

From another perspective, in our EMW, serial determination of PCT levels was not systematically assessed in 30% of patients who de-escalated; rather, the decision to proceed with ADE was a composite decision based on multiple factors, mainly the clinical stability of patients. Thus, as previously reported [16], this could explain the higher rate of ADE on day 5 (56%) compared to day 2 (21%) and day 3 (23%). The single-center nature of the study limits the generalizability of the results. Furthermore, the fact that the qSOFA scores did not differ significantly between groups, thus implying that the severity of the illness was similar, might be due to a lack of power, for the qSOFA is only based on three items. Other scores, like the classic SOFA score, might have provided a better discrimination of the severity of patients, although the added number of items makes them more suitable for the ICU than the EMW in daily practice.

Beyond the retrospective nature of this study, even if this result was influenced by several biases, namely an adjustment to the clinical course, the multivariate analysis of mortality indicated that both ADE and an appropriate empiric treatment were protective. The retrospective nature of our study did not allow us to draw any conclusions about the effectiveness of ADE. Furthermore, we restricted inclusion to patients with any BC performed and excluded those with specific infections (e.g., pneumonia).

5. Conclusions

Nevertheless, despite the aforementioned limitations, ADE is a promising approach even in an EMW setting. These results could encourage the implementation of biomarker use and wiser management of antibiotic therapy.

Author Contributions: Conceptualization, S.C. and F.G.D.R.; methodology, S.C. formal analysis, S.C. and S.M.P.; data curation, S.M.P.; writing—original draft preparation, S.M.P. and T.L.; writing—review and editing, A.T.; E.G.; R.C.; E.L.; supervision, F.G.D.R. Both authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Data acquisition and analysis was performed in compliance with protocols approved by the Ethical Committee of Città della Salute e della Scienza, Turin, Piedmont, Ethics Committee; Ethical approval number 0031285. The study was conducted according to the guidelines of the Declaration of Helsinki.

Informed Consent Statement: Written informed consent was waived in light of the methodology of the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Nathwani, D.; Varghese, D.; Stephens, J.; Ansari, W.; Martin, S.; Charbonneau, C. Value of hospital antimicrobial stewardship programs [ASPs]: A systematic review. Antimicrob. Resist. Infect. Control 2019, 8, 1–13. [CrossRef] [PubMed]
2. Viale, P.; Tedeschi, S.; Scudeller, L.; Attard, L.; Badia, L.; Bartoletti, M.; Cascavilla, A.; Cristini, F.; Dentale, N.; Fasulo, G.; et al. Infectious diseases team for the early management of severe sepsis and septic shock in the emergency department. Clin. Infect. Dis. 2017, 65, 1253–1259. [CrossRef] [PubMed]
3. Mathieu, C.; Pastene, B.; Cassir, N.; Martin-Loeches, I.; Leone, M. Efficacy and safety of antimicrobial de-escalation as a clinical strategy. *Expert Rev. Anti-Infect. Ther.* 2019, 17, 79–88. [CrossRef] [PubMed]

4. Tabah, A.; Bassetti, M.; Kollef, M.H.; Zahar, J.-R.; Paiva, J.-A.; Timsit, J.-F.; Roberts, J.A.; Schouten, J.; Giamarelou, H.; Rello, J.; et al. Antimicrobial de-escalation in critically ill patients: A position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) critically Ill patients study group (E SCCIP). *Intensiv. Care Med.* 2019, 46, 245–265. [CrossRef]

5. Dellit, T.H.; Owens, R.C.; McGowan, J.E., Jr.; Gerding, D.N.; Weinstein, R.A.; Burke, J.P.; Huskins, W.C.; Paterson, D.L.; Fishman, N.O.; Carpenter, C.F.; et al. Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. *Clin. Infect. Dis.* 2007, 44, 159–177. [CrossRef] [PubMed]

6. Dellit, T.H.; Cosgrove, S.E.; Abbo, L.M.; MacDougall, C.; Schuetz, A.N.; Septimus, E.J.; Srinivasan, A.; Dellit, T.H.; Falck-Ytter, Y.T.; Fishman, N.O.; et al. Implementing an antibiotic stewardship program: Guidelines by the infectious diseases society of America and the society for healthcare epidemiology of America. *Clin. Infect. Dis.* 2016, 62, e51–e77. [CrossRef] [PubMed]

7. Charani, E.; Ahmad, R.; Rawson, T.M.; Castro-Sánchez, E.; Tarrant, C.; Holmes, A.H. The differences in antibiotic decision-making between acute surgical and acute medical teams: An ethnographic study of culture and team dynamics. *Clin. Infect. Dis.* 2019, 69, 12–20. [CrossRef] [PubMed]

8. Schnell, D.; Montlahuc, C.; Bruneel, F.; Resche-Rigon, M.; Kouatchet, A.; Darmon, M.; Pene, F.; Lemiale, V.; Rabbat, A.; et al. De-escalation of antimicrobial therapy in critically ill hematology patients: A prospective cohort study. *Intensiv. Care Med.* 2019, 45, 743–745. [CrossRef] [PubMed]

9. Tabah, A.; Cotta, M.; Garnacho-Montero, J.; Schouten, J.; Roberts, J.; Lipman, J.; Tacey, M.; Timsit, J.-F.; Leone, M.; Zahar, J.R.; et al. A systematic review of the definitions, determinants, and clinical outcomes of antimicrobial de-escalation in the intensive care unit. *Clin. Infect. Dis.* 2016, 62, 1009–1017. [CrossRef] [PubMed]

10. Garnacho-Montero, J.; Gutiérrez-Pizarraya, A.; Escoresca-Ortega, A.; Corcia-Palomino, Y.; Fernández-Delgado, E.; Herrera-Melero, I.; Ortiz-Leyba, C.; Márquez-Vácaro, J.A. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. *Intensiv. Care Med.* 2014, 40, 32–40. [CrossRef] [PubMed]

11. Joug, M.K.; Lee, J.-A.; Moon, S.-Y.; Cheong, H.S.; Joo, E.-J.; Ha, Y.-E.; Sohn, K.M.; Chung, S.M.; Suh, G.Y.; Chung, D.R.; et al. Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia. *Crit. Care* 2011, 15, R79. [CrossRef] [PubMed]

12. Niimura, T.; Zanami, Y.; Imai, T.; Nagao, K.; Kayano, M.; Sagara, H.; Goda, M.; Okada, N.; Chuma, M.; Takechi, K.; et al. Evaluation of the benefits of de-escalation for patients with sepsis in the emergency intensive care unit. *J. Pharm. Pharm. Sci.* 2018, 21, 54–59. [CrossRef] [PubMed]

13. Povoa, P.; Salluh, J.I.F. Biomarker-guided antibiotic therapy in adult critically ill patients: A critical review. *Ann. Intensiv. Care* 2012, 2, 32. [CrossRef] [PubMed]

14. Petel, D.; Winters, N.; Gore, G.C.; Papenburg, J.; Beltempo, M.; Lacroix, J.; Fontela, P.S. Use of C-reactive protein to tailor antibiotic use: A systematic review and meta-analysis. *BMJ Open* 2018, 8, e022133. [CrossRef] [PubMed]

15. Ryoo, S.M.; Korean Shock Society (KoSS) Investigators; Han, K.S.; Ahn, S.; Shin, T.G.; Hwang, S.Y.; Chung, S.P.; Hwang, Y.J.; Park, Y.S.; Jo, Y.H.; et al. The usefulness of C-reactive protein and procalcitonin to predict prognosis in septic shock patients: A multicenter prospective registry-based observational study. *Sci. Rep.* 2019, 9, 6579. [CrossRef] [PubMed]

16. Van Heijl, I.; Schweitzer, V.A.; Van Der Linden, P.D.; Bonten, M.J.; Van Werkhoven, C.H. Impact of antimicrobial de-escalation on mortality: A literature review of study methodology and recommendations for observational studies. *Expert Rev. Anti-Infect. Ther.* 2020, 18, 405–413. [CrossRef] [PubMed]